Want to see HK:8225 full AI Analyst Report?
China Health Group Inc. (8225) Ratios
China Health Group Inc. Ratios
HK:8225's free cash flow for Q4 2025 was $-980.00K. For the 2025 fiscal year, HK:8225's free cash flow was decreased by $-5.00K and operating cash flow was $-975.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.17 | 2.97 | 3.19 | 4.82 | 4.53 |
| Quick Ratio | 2.17 | 2.97 | 3.19 | 4.82 | 4.53 |
| Cash Ratio | 0.72 | 0.45 | 0.12 | 0.11 | 0.27 |
| Solvency Ratio | -0.44 | -0.45 | -1.64 | -0.43 | 0.86 |
| Operating Cash Flow Ratio | 0.28 | 0.33 | 0.03 | -0.14 | -0.24 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 37.95M | $ 61.39M | $ 77.01M | $ 140.48M | $ 150.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.57 | 1.44 | 1.41 | 1.26 | 1.27 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -922.06 | 2436.07 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -944.53 | 2805.80 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 1.67 | 1.00 | 0.07 | 0.26 | -0.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.39% | 38.05% | 38.33% | 43.87% | 76.38% |
| EBIT Margin | -51.95% | -56.12% | -271.70% | -120.77% | 50.88% |
| EBITDA Margin | -50.49% | -53.83% | -270.60% | -119.62% | 51.12% |
| Operating Profit Margin | -51.95% | -56.12% | -267.57% | -122.67% | 50.34% |
| Pretax Profit Margin | -52.38% | -54.71% | -271.70% | -120.90% | 50.86% |
| Net Profit Margin | -52.38% | -54.88% | -270.78% | -121.03% | 43.45% |
| Continuous Operations Profit Margin | -52.38% | -54.88% | -271.70% | -120.90% | 43.45% |
| Net Income Per EBT | 100.00% | 100.32% | 99.66% | 100.11% | 85.43% |
| EBT Per EBIT | 100.84% | 97.49% | 101.54% | 98.56% | 101.03% |
| Return on Assets (ROA) | -16.73% | -14.38% | -48.61% | -8.87% | 18.34% |
| Return on Equity (ROE) | -26.30% | -20.64% | -68.40% | -11.13% | 23.35% |
| Return on Capital Employed (ROCE) | -26.39% | -21.29% | -68.10% | -11.32% | 27.05% |
| Return on Invested Capital (ROIC) | -26.39% | -21.29% | -68.10% | -11.32% | 23.69% |
| Return on Tangible Assets | -16.73% | -14.38% | -48.61% | -8.87% | 18.34% |
| Earnings Yield | -11.17% | -7.81% | -46.61% | -6.22% | 11.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.66 | 0.46 | 0.33 | 0.12 | 0.64 |
| Payables Turnover | 27.50 | 33.44 | 2.38 | 1.27 | 2.78 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 11.98 | 9.70 | 2.99 | 9.36 | 53.94 |
| Asset Turnover | 0.32 | 0.26 | 0.18 | 0.07 | 0.42 |
| Working Capital Turnover Ratio | 0.56 | 0.38 | 0.20 | 0.09 | 0.63 |
| Cash Conversion Cycle | 539.51 | 783.60 | 961.05 | 2748.79 | 438.77 |
| Days of Sales Outstanding | 552.79 | 794.52 | 1114.15 | 3036.14 | 569.93 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 13.27 | 10.91 | 153.09 | 287.35 | 131.16 |
| Operating Cycle | 552.79 | 794.52 | 1114.15 | 3036.14 | 569.93 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.01 | 0.01 | 0.00 | -0.01 | -0.01 |
| Free Cash Flow Per Share | 0.01 | 0.01 | -0.00 | -0.01 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 927.40 | 5.84 | 0.19 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 927.40 | 5.84 | 0.19 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.32 | 0.39 | 0.05 | -0.39 | -0.12 |
| Free Cash Flow Yield | 6.91% | 4.59% | -3.92% | -2.02% | -3.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.98 | -12.80 | -2.15 | -16.09 | 8.59 |
| Price-to-Sales (P/S) Ratio | 4.69 | 7.03 | 5.81 | 19.47 | 3.73 |
| Price-to-Book (P/B) Ratio | 2.36 | 2.64 | 1.47 | 1.79 | 2.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 14.47 | 21.81 | -25.49 | -49.43 | -30.37 |
| Price-to-Operating Cash Flow Ratio | 14.45 | 18.07 | 111.03 | -49.43 | -30.37 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.17 | -0.01 | 0.11 | -0.21 |
| Enterprise Value Multiple | -7.62 | -12.06 | -2.08 | -16.02 | 7.04 |
| Enterprise Value | 107.09M | 171.68M | 120.32M | 250.82M | 300.72M |
| EV to EBITDA | -7.62 | -12.06 | -2.08 | -16.02 | 7.04 |
| EV to Sales | 3.85 | 6.49 | 5.62 | 19.16 | 3.60 |
| EV to Free Cash Flow | 11.87 | 20.14 | -24.64 | -48.65 | -29.26 |
| EV to Operating Cash Flow | 11.86 | 16.69 | 107.33 | -48.65 | -29.26 |
| Tangible Book Value Per Share | 0.06 | 0.07 | 0.08 | 0.14 | 0.16 |
| Shareholders’ Equity Per Share | 0.06 | 0.07 | 0.09 | 0.14 | 0.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | -0.00 | 0.15 |
| Revenue Per Share | 0.03 | 0.03 | 0.02 | 0.01 | 0.08 |
| Net Income Per Share | -0.01 | -0.01 | -0.06 | -0.02 | 0.04 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.85 |
| Interest Burden | 1.01 | 0.97 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.09 | 0.94 | 0.36 | 1.07 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.02 | 0.16 | 0.01 |
| Income Quality | -0.62 | -0.71 | -0.02 | 0.33 | -0.24 |
Currency in CNY
